HCV is a major cause of liver cancer, and treatment of patient-derived cancer cells with monoclonal antibodies against claudin-1, the receptor for HCV, suppresses liver cancer growth in ex vivo models (Nehme et al., 2023). Here, CLDN1 is linked to liver cancer.